Artal Group’s Viridian Therapeutics VRDN Stock Holding History

Artal Group’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-504,978	Closed	-$7.75M	–	112
2023 Q3	$7.75M	Hold	504,978	–	–	0.33%	50
2023 Q2	$12M	Hold	504,978	–	–	0.37%	41
2023 Q1	$12.8M	Buy	+504,978	New	+$16.2M	0.76%	33
2019 Q2	–	Sell	-33,333	Closed	-$1.4M	–	117
2019 Q1	$1.4M	Hold	33,333	–	–	0.06%	99
2018 Q4	$1.51M	Hold	33,333	–	–	0.06%	98
2018 Q3	$2.79M	Hold	33,333	–	–	0.07%	92
2018 Q2	$3.21M	Hold	33,333	–	–	0.07%	83
2018 Q1	$3.5M	Buy	33,333 +26,666	+400%	+$2.9M	0.04%	84
2017 Q4	$1.04M	Hold	6,667	–	–	0.02%	111
2017 Q3	$915K	Buy	+6,667	New	+$1.12M	0.02%	109

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Artal Group's VRDN Position: Q4 2023 in Review

Artal Group sold out of Viridian Therapeutics (VRDN) in Q4 2023, closing a stake of 504,978 shares — an estimated $7.75M sold.

Artal Group first reported a position in VRDN in Q3 2017 and held it in 10 quarters. The position peaked at $12.8M in Q1 2023. 132 funds tracked by Wall St. Rank hold VRDN as of Q4 2023.

Artal Group reported no remaining Viridian Therapeutics position as of Q4 2023 after selling out during the quarter.
Artal Group sold 504,978 Viridian Therapeutics shares in Q4 2023, an estimated $7.75M.
Artal Group first reported a position in Viridian Therapeutics in Q3 2017 and held it in 10 quarters.
Artal Group's Viridian Therapeutics position peaked at $12.8M in Q1 2023.
132 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q4 2023.

Based on Artal Group's 13F filing for Q4 2023, filed 9 Feb 2024.